Hepatitis C Challenge: Caring Ambassadors Hep C Program
 HepC Choices

Hepatitis News:

May 2006

Largest U.S. Hepatitis C Trial Provides Insight Into Optimizing Treatment for Patients
"Researchers who participated in the WIN-R trial, the largest hepatitis C study ever conducted in U.S. patients, reported key factors affecting treatment outcomes in five data presentations here at the Digestive Disease Week (DDW) annual meeting, and provided important insights for optimizing treatment with PEG-INTRON® (peginterferon alfa-2b) and REBETOL® (ribavirin, USP) combination therapy for patients with chronic hepatitis C virus (HCV) infection, a potentially deadly liver disease."

InterMune announces hepatitis C research
"Drug maker InterMune Inc. said Tuesday preclinial data show the company's hepatitis C virus protease inhibitor, ITMN-191, is active against variants of the disease that are less sensitive to other experimental hepatitis protease inhibitors in development."

Vertex jumps on hepatitis C drug advancement
"According to Vertex chief executive officer Joshua Boger, Vertex Pharmaceuticals Inc.has already started a large-scale Phase IIb trial clinical trial in the U.S. that will test to see how long VX-950 can keep the body clear of the liver-destroying virus."

Enzyme-blocking Drug Offers Hope for Hepatitis C Sufferers
"ViroPharma, Inc. said Sunday that data from a phase 1b trial of an enzyme-blocking drug showed a 97 percent success rate in preventing the Hepatitis C virus from replicating itself."

Difficulty in treating older hepatitis C patients with Interferon and Ribavirin
"A study in Japan examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group."

Hepatitis C Update
"A new study shows viral hepatitis C--a deadly liver infection--is becoming more prevalent in those over 40--among the baby boomers who are aging."

Celera To Announce Test for Cirrhosis in Hepatitis C Patients
"Maryland-based Celera Genomics on Wednesday was expected to announce a genetic test that it says could predict if a patient with hepatitis C is likely to develop cirrhosis of the liver, the New York Times reports."

Human Genome Sciences Presents Interim Results of Phase 2 Trial of Albuferon(TM) with Ribavirin in Patients with Chronic Hepatitis C Who Failed to Respond to Previous Therapy
"Human Genome Sciences, Inc. today reported the interim results of a Phase 2 clinical trial to evaluate the safety, tolerability and efficacy of Albuferon(TM) (albumin-interferon alpha 2b) in combination with ribavirin in patients with chronic hepatitis C (HCV) who failed to respond to previous interferon alpha-based treatment regimens."

Hepatitis C Patients Benefit From Combination Of VX-950 And Pegylated Interferon
"The experimental oral protease inhibitor VX-950, dosed in combination with pegylated interferon alfa-2a (PegasysR; peg-IFN), is potent and well tolerated in patients with chronic genotype 1 hepatitis C virus (HCV) infection, researchers announced at the 41st Annual Meeting of the European Association for the Study of the Liver (EASL)."

Saint Louis University hunt for a Hepatitis C vaccine
"Human clinical trials involving investigational vaccines to prevent Hepatitis C are rare. In the fall of 2003 there was a first-ever study at Saint Louis University Center for Vaccine Development, and an earlier small study at Johns Hopkins School of Medicine."

Employer pays $24,000 for Hepatitis C firing
"ST. LOUIS - A former convenience store employee who was fired for having Hepatitis C has been awarded $24,000 in a lawsuit settlement, the U.S. Equal Employment Opportunity Commission said Thursday."

Roche study shows hepatitis C patients need six months of treatment
"Roche has posted results from a new trial showing that 24 weeks of therapy with Pegasys combined with ribavirin is more effective than 16 weeks for patients infected with hepatitis C genotypes 2 and 3."

AVI BioPharma shares plunge on hepatitis C data
"Shares of AVI BioPharma Inc. lost a third of their value on Wednesday after the company reported disappointing clinical trial data for its experimental treatment against the hepatitis C virus."

Clinical Trials, Cohort Studies, Pilot Studies

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Armstrong GL, et al. Ann Intern Med. 2006 May 16;144(10):705-14.

Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. Santoro L, et al. J Neurol Neurosurg Psychiatry. 2006 May;77(5):626-9. Epub 2006 Feb 7.

Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation.
Melum E, Schrumpf E, Bjoro K. Scand J Gastroenterol. 2006 May;41(5):592-6.

Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. Muir AJ, Sylvestre PB, Rockey DC. J Viral Hepat. 2006 May;13(5):322-8.

Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis.
Butt AA, Evans R, Skanderson M, Shakil AO. J Hepatol. 2006 May;44(5):864-8. Epub 2006 Feb 20.

Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. Aberle JH, et al. J Clin Virol. 2006 May;36(1):24-31. Epub 2006 Feb 17.

Myocarditis and heart failure associated with hepatitis C virus infection. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. J Card Fail. 2006 May;12(4):293-8.

Hepatitis C virus infection in a resident elderly population: A 10-year follow-up study. Monica F, et al. Dig Liver Dis. 2006 May;38(5):336-40. Epub 2006 Apr 14.

Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
Hiramatsu N, et al. Hepatol Res. 2006 May 3; [Epub ahead of print]

Acute hepatitis C virus infection in incarcerated injection drug users. McGovern BH, et al. Clin Infect Dis. 2006 Jun 15;42(12):1663-70. Epub 2006 May 11.

Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Farci P, et al. Proc Natl Acad Sci U S A. 2006 May 17; [Epub ahead of print]

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Firbas C, et al. Vaccine. 2006 May 15;24(20):4343-53. Epub 2006 Mar 20.

Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial.
Fontana RJ, et al. Am J Gastroenterol. 2006 May 11;101(5):983-92. Epub 2006 Mar 30.

Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Weissenborn K, et al. Gut. 2006 May 8; [Epub ahead of print]

Relationship of Smoking and Fibrosis in Patients With Chronic Hepatitis C. Dev A, Patel K, Conrad A, Blatt LM, McHutchison JG. Clin Gastroenterol Hepatol. 2006 May 5; [Epub ahead of print]

Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ferreri AJ, et al. Ann Oncol. 2006 May;17(5):769-72. Epub 2006 Mar 8.

Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: a 12-year prospective study. Tanaka K, Nagao Y, Ide T, Kumashiro R, Sata M. Int J Mol Med. 2006 May;17(5):827-32.

Improvement in quality of life measures in patients with refractory hepatitis C, responding to retreatment with Pegylated interferon alpha-2b and ribavirin. Mathew A, Peiffer LP, Rhoades K, McGarrity TJ. Health Qual Life Outcomes. 2006 May 12;4(1):30 [Epub ahead of print]

Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission. Caseiro MM. Rev Inst Med Trop Sao Paulo. 2006 Mar-Apr;48(2):109-12. Epub 2006 May 8.

Determinants of quality of life in chronic liver patients. Gutteling JJ, et al. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1629-35.

Basic And Applied Science, Pre-Clinical Studies

Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C. Guido M, et al. Mod Pathol. 2006 May 12; [Epub ahead of print]

Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells. Naka K, et al. J Hepatol. 2006 May;44(5):869-78. Epub 2006 Feb 28.

The effect of HCV core protein on the expression of cyclooxygenase 2 (COX-2) in HepG2 cells.
Liu YL, et al. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 May;22(3):343-5. [Article in Chinese]

Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Pietschmann T, et al. Proc Natl Acad Sci U S A. 2006 May 9;103(19):7408-13. Epub 2006 May 1

Fas Ligand Is Responsible for CXCR3 Chemokine Induction in CD4+ T Cell-Dependent Liver Damage.
Cruise MW, et al. J Immunol. 2006 May 15;176(10):6235-44.

HIV/HCV Coinfection

The Association of Cigarette Smoking with HIV Prognosis Among Women in the HAART Era--A Report From the Women's Interagency HIV Study. Feldman JG, Am J Public Health. 2006 May 2; [Epub ahead of print]

Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs. Maida I, J Acquir Immune Defic Syndr. 2006 May 8; [Epub ahead of print]

Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Weis N, et al. Clin Infect Dis. 2006 May 15;42(10):1481-7. Epub 2006 Apr 12.

Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. AIDS. 2006 May 12;20(8):1171-1179.

Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. Dominguez S, et al. AIDS. 2006 May 12;20(8):1157-1161.

Assessing the reproductive performance of men co-infected with HIV-1 and hepatitis C undergoing assisted reproduction. Chu MC, et al. Arch Gynecol Obstet. 2006 May 5; [Epub ahead of print]

Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
Al-Harthi L, J Infect Dis. 2006 May 1;193(9):1202-10. Epub 2006 Mar 17.

Complementary And Alternative Therapies

The pharmacological effects of Salvia species on the central nervous system. Imanshahidi M, Hosseinzadeh H. Phytother Res. 2006 Jun;20(6):427-37.

Miscellaneous Works

A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for hepatitis C. Yeh CT, et al. J Infect Dis. 2006 May 15;193(10):1365-70. Epub 2006 Apr 12.

Variability of grade and stage in simultaneous paired liver biopsies in Hepatitis C. Skripenova S, Trainer T, Krawitt E, Blaszyk H. J Clin Pathol. 2006 May 12; [Epub ahead of print]

Evaluation of the performance of 44 assays used in countries with limited resources for the detection of antibodies to hepatitis C virus. Scheiblauer H, El-Nageh M, Nick S, Fields H, Prince A, Diaz S. Transfusion. 2006 May;46(5):708-18.

Evolution of infection control in Egypt: Achievements and challenges. Talaat M, Am J Infect Control. 2006 May;34(4):193-200.

Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.
Kleinman SH, Stramer SL, Brodsky JP, Caglioti S, Busch MP. Transfusion. 2006 May;46(5):695-702.


Donate Now Give a gift in celebration
Give a gift in memory
Shop for Us

Hepatitis C is the most common, chronic blood-borne
viral infection in the U.S.